P783: CLINICAL, HUMANISTIC, AND ECONOMIC BURDEN IN PATIENTS WITH PNH RECEIVING C5 INHIBITION TREATMENT ACROSS UK, GERMANY, AND FRANCE. INSIGHTS FROM THE COMMODORE BURDEN OF ILLNESS STUDY
Louis Terriou,
Maria Piggin,
Pascale Burmester,
Fengkui Zhang,
Alan Finnegan,
Persefoni Kritikou,
Claudia Mighiu,
Christian Buehrer,
Pablo Katz,
Selma Mode,
Xenia Studera,
Huong Trinh,
Talha Munir
Affiliations
Louis Terriou
1 Service de Medicine Interne – Hematologie, CHRU de Lille, Lille, France
Maria Piggin
2 PNH Support, London, United Kingdom
Pascale Burmester
3 Stiftung Lichterzellen, Köln, Germany
Fengkui Zhang
4 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical University, Beijing, China
Alan Finnegan
5 University of Chester, chester, United Kingdom
Persefoni Kritikou
6 HCD Economics, Chester, United Kingdom
Claudia Mighiu
6 HCD Economics, Chester, United Kingdom
Christian Buehrer
7 F. Hoffmann-La Roche Ltd, Basel, Switzerland
Pablo Katz
7 F. Hoffmann-La Roche Ltd, Basel, Switzerland
Selma Mode
7 F. Hoffmann-La Roche Ltd, Basel, Switzerland
Xenia Studera
7 F. Hoffmann-La Roche Ltd, Basel, Switzerland
Huong Trinh
8 Genentech, Inc., South San Francisco, CA, United States
Talha Munir
9 Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom
